Efficacy of probiotics in preventing of post COVID-19 syndrome (Long COVID)

Status

Unknown

Phases

Phase 2

Study type

Interventional

Source

TCTR

Registry ID

TCTR20240920005

Enrollment

220

Registered

2024-09-20

Start date

2024-01-01

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Efficacy of probiotics in preventing of post COVID-19 syndrome (Long COVID) COVID-19, prevention, probiotics, symptoms

Interventions

Probiotics capsule 500 mg oral daily dose for 4 weeks,Placebo capsule 500 mg oral daily dose for 4 weeks

Experimental Drug,Placebo Comparator Drug

Probiotics,Placebo

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Age 18-60 years. 2. Confirm diagnosis of COVID-19, measure from RT-PCR who presents with symptomatic COVID without pneumonia and no risk factors for severe disease. 3. Not received anti-viral drugs such as favipiravir, remdesivir, moluration, nupiravir, nirmatrevir/nitonavir. 4. Peripheral oxygen saturation SpO2 > 95% 5. Have no the history contacts COVID-19 in 3 months ago.

Exclusion criteria

Exclusion criteria: 1. The participants have no symptoms or asymptomatic COVID-19. 2. The participants have a risk factors such as pneumonia, chronic obstructive pulmonary disease, chronic kidney disease, cardiovascular disease, stroke, poorly controlled diabetes mellitus, obesity, cirrhosis, Immune deficiency disease and people living with HIV. 3. The participants have adverse effect of probiotics. 4. Pregnancy and lactating women. 5. Caution with probiotics e.g. immunocompromise, prosthetic heart values, impaired intestinal function, central venous catheter, jejunostomy, broad-spectrum antimicrobials and poorly controlled diabetes mellitus. 6. The participants who allegic to hypromellose. 7. The participants who has history of isomalt allergy or silicon dioxide.

Design outcomes

Primary

Measure	Time frame
Comparison of Long COVID incidence between probiotics and control groups 8, 16, 24 weeks Diagnosis long COVID from questionnaire; mMRC, ISI, TMSE, GAD-7 and 9Q.	—

Secondary

Measure	Time frame
1) Quality of life , 2) Function status, 3) Complications 8, 16, 24 weeks 1) Questionnaire SF-36, 2) Questionnaire Post COVID-19 function status (PCFS), 3) Adverse effects	—

Countries

Thailand

Contacts

Public ContactPanuwat Wongwattana

Srinakharinwirot University

panuwatw@g.swu.ac.th037395451

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Apr 4, 2026